Successful ventricular tachycardia (VT) ablation is associated with improved survival in patients with heart failure. However, the safety and efficacy of VT ablation in the elderly, a population with higher competing nonsudden death risk and comorbidities, have not been well defined.
A lthough implantable cardioverter-defibrillators (ICDs) are the mainstay of therapy for sudden cardiac death reduction in patients with ventricular tachycardia (VT) or ventricular fibrillation, 1, 2 ICD shocks are painful and associated with increased physical and psychological morbidity and mortality. Catheter ablation for VT has been recently shown to be superior to escalation of antiarrhythmic therapy in reducing the composite end point of death, VT storm, and ICD shocks in a large randomized clinical trial. 3 Our group also recently published the real-world experience highlighting the safety and efficacy of VT ablation from a large international registry of >2000 patients and showed that successful VT ablation is associated with improved long-term survival. 4 However, there remains a paucity of data on safety and efficacy of VT ablation in elderly patients who tend to have a relatively higher risk of nonsudden death and more significant comorbidities. In prior reports, some authors from our group have previously shown that outcomes of VT ablation tend to be similar among the young and the elderly patients. 5 However, all prior studies addressing catheter ablation in the elderly have either been limited by a small sample size or have included few patients who underwent ablation for VT. [6] [7] [8] [9] [10] Given the lack of large-scale data in the elderly population, understandably clinicians at times are hesitant in performing high-risk ablations in this group. To that regard, in a large European Heart Rhythm Association survey from 20 countries, 11 ≈35% of centers reported having an upperage boundary for offering VT ablation to their patients.
As such in this IVTCC study (International Ventricular Tachycardia Center Collaborative Group), we sought to determine whether VT ablation in the elderly is (1) safe, and (2) continues to offer similar survival benefit as compared with their younger counterparts.
WHAT IS KNOWN?
• Successful ventricular tachycardia (VT) ablation is associated with improved survival in patients with heart failure. However, the safety and efficacy of VT ablation in the elderly have not been well defined.
• In a recent large European Heart Rhythm Association survey from 20 countries, ≈35% of centers reported having an upper-age boundary for offering VT ablation to their patients.
WHAT THE STUDY ADDS?
• Although elderly patients have higher baseline comorbidities, VT ablation in this population is reasonably safe with a similar incidence of procedural complications as compared with younger patients.
• Elderly patients have ≈2-fold higher in-hospital mortality and a modestly higher 1-year mortality compared with their younger counterparts.
• Although long-term survival is expectedly worse in the elderly population, the rates of VT recurrence and time to VT recurrence are not significantly different between patients > or <70 years.
• Importantly, successful VT ablation, that is, lack of VT recurrence during follow-up, seems to be associated with a significantly improved survival in the elderly.
METHODS Data Source: IVTCC Group
The IVTCC study group currently includes 12 participating international tertiary-care centers that perform complex VT ablations. These centers collectively have developed a shared registry that includes patients who underwent VT ablation between the years 2002 and 2013. Patient inclusion and exclusion criteria in the IVTCC cohort have been previously described. 4, 12 In this IVTCC registry, elements of past medical history were defined according to American College of Cardiology Foundation/American Heart Association task force on clinical data standards. 13 The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Patients
Adults (≥18 years old) who underwent VT ablation and were included in the IVTCC registry were included in this study. Patients with missing data on survival, VT recurrence, or age were excluded. The final study cohort consisted of 2061 patients. Patients were stratified into 2 groups based on their age (< or ≥70 years). Sensitivity analyses were performed by changing the age cutoff to 75 years for stratification.
Ablation and Procedural Data Collection
Procedural details and ablation strategies have been previously described. 4, 12 Specifically, contemporary approaches for substrate-based ablation guided by electroanatomic mapping, pace mapping, and when feasible, activation and entrainment mapping were performed across all centers. Acute ablation success was defined as noninducibility of sustained, monomorphic VT with programmed extrastimulation (PES) after ablation. PES was performed unless precluded by hemodynamic instability or other patient safety risk.
Outcomes
The primary safety outcome was a composite of major complications that included vascular access-related major bleeding, pericardial effusion leading to pericardiocentesis or surgical repair, coronary injury, stroke, thromboembolism, or procedural death. Secondary safety outcome was the incidence of in-hospital mortality before discharge.
Primary efficacy outcome was 1-year all-cause mortality after VT ablation. Secondary outcomes were 1-year incidence of VT recurrence and time to VT recurrence. Given that few patients in this cohort underwent heart transplantation after ablation, and the eligibility of transplantation would be biased by the age stratification used in this study, this was not considered as a study outcome. Patients were censored at the time of heart transplantation.
Statistical Analyses
Continuous variables are summarized as mean±SD or median (25th, 75th percentile) and categorical variables as frequency (n) and percentage (%). Mann-Whitney tests or t tests were used to compare continuous variables. χ 2 tests or Fisher exact tests were used for categorical variables. Kaplan-Meier curves were used to assess survival and VT recurrence in individual patient groups. To assess the impact of successful ablation on long-term outcomes in the elderly, the effect of VT recurrence on survival was assessed by Kaplan-Meier analysis in subgroup of patients ≥70 years of age. Kaplan-Meier curves were compared using the logrank test.
Cox proportional-hazards regression analysis was performed to adjust for the following covariates (sex, New York Heart Association functional class, diabetes mellitus, atrial fibrillation, chronic kidney disease, preablation left ventricular ejection fraction [EF] , VT storm at presentation, successful VT ablation, and recurrence of VT during follow-up). The final model was determined by entering variables with a P<0.05 and removing variables with a P>0.01. For each age group (< or ≥70 years of age), postdischarge rates of mortality were calculated based on person-time, which reports the number of new events divided by the sum of person-years at risk.
Sensitivity analyses, including survival according to VT recurrence during follow-up, were performed by analyzing outcomes in groups of patients < or ≥75 years. All comparisons were 2 sided, and a P≤0.05 was considered as statistically significant. Analyses were performed using MedCalc Version 17.2. The study was approved by the institutional review board at each respective institution included in the IVTCC group. All authors had access to all data and have contributed to the structure and content of the article.
RESULTS

Patient Characteristics
Total of 2061 patients with structural heart disease underwent VT ablation at 12 centers. Of these, 12 patients had missing information and were excluded. Of the remaining 2049 patients (median age, 65 years; interquartile range, 55-72 years) who were included in the analysis, 1368 (67%) were <70 years (mean age, 56±10 years) and 681 (33%) were ≥70 years (mean age, 75±4 years). Frequency distribution of patients by age is provided in the Data Supplement (Figure I Data Supplement). Ischemic cardiomyopathy was present in 53% of patients. Clinical characteristics of patients included are shown in Table 1 . Compared with patients <70 years, patients ≥70 years were more often men and had higher incidence of ischemic cardiomyopathy, hypertension, diabetes mellitus, or chronic kidney disease. The mean left ventricular EF was lower in patients ≥70 years (30±11% versus 34±13%; P<0.001). Furthermore, a significantly higher proportion of patients in ≥70 years group had VT storm or incessant VT as the indication for their VT ablation (42% versus 31%; P<0.001) and use of antiarrhythmic therapy, particularly amiodarone, for VT (86% versus 71%; P<0.001) compared with patients <70 years. Table 2 highlights the important procedural characteristics in both patient groups. Given the higher prevalence of prior thoracic surgery in patients ≥70 years, epicardial ablation was less commonly performed in this group relative to patients <70 years of age (23% versus 35%; P<0.001).
Procedural Safety and Immediate Success
A final PES to assess for VT inducibility was performed in 95% of patients in each group. Acute procedural success was achieved in 65% patients in the ≥70-year group and 67% in the <70-year group (P=0.49). When compared with patients <70 years, patients ≥70 years had higher in-hospital mortality (4.4% versus 2.3%; P=0.01). The need for periprocedural hemodynamic support (6% versus 5%; P=0.50; Table 2 ) and rates of procedural complications (8% versus 7%; P=0.34) were not significantly different between the 2 groups (Table 3) .
Efficacy Outcomes Stratified by Age
When compared with patients <70 years, patients ≥70 years had higher 1-year mortality (15% versus 11%; P=0.002) after VT ablation (Table 3) . Overall long-term survival after VT ablation was significantly better for patients <70 years ( Figure 1 ). Mortality rate (incidence rate) for patients <70 years of age was 0. Continuous variables are reported as mean±SD and categorical variables as n (%). % calculation accounts for missing data and rounded to the nearest integer. CRT-D indicates cardiac resynchronization therapy defibrillator; ICD, implantable cardioverter-defibrillator; LV EF, left ventricular ejection fraction; and VT, ventricular tachycardia. *P for trend. Categorical variables are reported as n (%).VT indicates ventricular tachycardia.
*Complications included vascular access-related major bleeding, pericardial effusion leading to pericardiocentesis or surgical repair, coronary injury, stroke, thromboembolism, or procedural mortality. 
Predictors of Mortality After VT Ablation in Patients ≥70 Years
Using Cox proportional-hazards regression analysis, the following covariates were predictive of long-term mortality: New York Heart Association functional class, VT storm at presentation, lack of procedural success, that is, sustained VT inducibility during PES after ablation, low preablation left ventricular EF, and VT recurrence during follow-up (Table 4 ). Figure 3 highlights the impact of VT recurrence on long-term survival in elderly patients. Similar findings were noted in patients <70 years of age ( Figure IV in the Data Supplement).
Sensitivity Analyses for Patients ≥75 Years
Sensitivity analyses were performed for patients ≥75 years (n=371). When compared with patients <75 years, patients ≥75 years had higher in-hospital (4.6% versus 2.7%; P=0.05) and 1-year mortality (17% versus 12%; P=0.008) after VT ablation. Absence of VT recurrence during follow-up was similarly associated with a significantly improved survival in patients ≥75 years of age as well (Figure 4 ).
DISCUSSION
The current study, the largest to date, provides insight into the safety, feasibility, and efficacy of VT ablation in elderly patients with both ischemic and nonischemic heart disease. Our findings suggest that VT ablation in the elderly, despite the presence of higher baseline comorbidities in this group, is reasonably safe with a similar incidence of procedural complications as compared with younger patients. However, elderly patients had ≈2-fold higher in-hospital mortality and a modestly higher 1-year mortality compared with their younger counterparts. Acute procedural success, that is, noninducibility of sustained VT after ablation was achieved in nearly two thirds of patients in each group. Although long-term survival was expectedly worse in the elderly population, the rates of VT recurrence during follow-up and time to VT recurrence were not significantly different. Most importantly, successful VT ablation without VT recurrence during follow-up was associated with a significantly improved survival in elderly patients.
It should be emphasized that 42% of elderly patients in our study had VT storm or incessant VT at presentation, suggesting the inclusion of a rather sick group of patients in this study. More than half had ischemic cardiomyopathy, and the mean EF was severely reduced at 30%. In addition to VT storm at presentation, having a low EF before ablation and lack of procedural success (ie, inducible sustained VT post-ablation) significantly predicted higher 1-year mortality. Although the incidence of VT recurrence at 1-year in the elderly subgroup was similar to younger patients (≈1 in 4 patients), absence of VT recurrence during follow-up was associated with a significantly improved survival in the elderly subgroup.
Prior reports addressing procedural safety and efficacy of catheter ablations in the elderly have either been limited by a small sample size or have included few patients undergoing VT ablation. [5] [6] [7] [8] [9] [10] In a previous report by Inada et al, 5 outcomes of VT ablation in a high-risk cohort of postinfarct recurrent VT were not significantly different between older and younger patients. Similar results were noted in a recent report by Barra et al, 6 however the age cutoff for study entry was 60 years and secondly the study was underpowered.
In this study, we empirically chose an age cutoff of 70 years given the relative under-representation of patients greater than this age in most landmark ICD/sudden death trials. 1, 2, 14 Although prior randomized VT trials have included a reasonable proportion of patients with age ≥70 years, the overall sample size in those trials was rather small. Still it is important to note that on subgroup analyses of the VANISH (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease; overall n=259) and SMASH-VT (The Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia; overall n=128) trials, VT ablation was associated with ≈30% to 70% reduction in rates of subsequent ICD therapies or death in patients ≥70 years. 3, 15 Furthermore, in the Thermocool VT ablation trial (irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction) of 231 patients (mean age, 68 years), age was not a predictor of outcome on multivariable analyses. 16 Unfortunately, however, none of these trials directly compared outcomes of elderly and younger patients. Barra et al 6 recently showed that in their cohort there was a much higher clinical threshold for performing VT ablation in the elderly-only 1 procedure in the elderly was elective as opposed to 40% procedures performed electively in younger patients. Similar results were noted in this current analysis wherein VT storm/incessant VT as the indication for ablation was significantly higher in the elderly group as compared with younger patients. Interestingly, in a recent large international survey that included 49 centers in 20 countries, it was noted that rates of ablation for VT, and particularly atrial fibrillation, were significantly lower in the elderly. 11 These findings suggest that perhaps many centers tend to have an upper-boundary for age when considering patients for VT ablation, especially electively. In addition, as noted in the present analyses, use of antiarrhythmic therapy tends to be much higher in the elderly population, 5 probably raising another speculation that clinicians may choose to be more conservative by favoring escalation of medical therapy and perhaps simultaneously delaying VT ablation in elderly patients because of possible concerns of procedural safety and efficacy.
Certain limitations and inherent potential biases should be considered while interpreting results of this retrospective observational multicenter cohort study. Limitations applicable to the IVTCC cohort have been previously described 4 and would similarly apply to the current analyses. The following issues merit consideration. Centers included in the IVTCC group include only those with expertise in complex ablations, heart failure care, and ability to provide ongoing advanced periprocedural hemodynamic support if required. Therefore, generalizability of these findings to centers lacking such expertise should be made with caution. Given that elderly patients have a proportionately higher risk of nonsudden death, assessing impact of VT ablation on sudden death reduction in the elderly would have been ideal. Unfortunately, mode of death could not be assessed in this study. Impact of certain clinical variables that were not captured in this large collaborative data set could not be accounted for. Given the retrospective nature of this analysis, no standardized protocols were established among centers for PES after VT ablation. Last, although our findings remained consistent when we changed our age cutoff to ≥75 years, it is possible that with increasing age, there would be an increasing inherent selection bias such that VT ablations would be offered only to the healthiest elderly patients rather than those with more extensive comorbidities.
In conclusion, catheter ablation for VT in appropriately selected patients >70 (or 75) years of age is feasible and relatively safe with a slightly higher in-hospital and 1-year mortality. Although the elderly expectedly have worse long-term survival than younger patients, successful VT ablation without future VT recurrences is associated with significantly improved survival in the elderly. 
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